Parkinson's Disease Clinical Trial Pipeline Boom as 150+ Companies are in the Race for Better Treatments | DelveInsight DelveInsight's 'Parkinson's Disease Pipeline Insight 2026' report provides ...

Researchers ranked 83 preclinical candidates for preventing or treating preeclampsia and eclampsia, identifying 11 as having ...

Arshad M. Khanani, MD, MA, discusses phase 3 SOL-1 data showing axitinib sustained vision in wet AMD for 9-12 months after 1 ...

First selective MET inhibitor approved for patients with MET-amplified advanced gastric cancer or gastroesophageal junction adenocarcinoma in China ...

Learn about notable updates that occurred in June 2026 for investigational products in development (not an inclusive list).

The key secondary endpoints found the PsO pill to be beneficial in high-impact areas, including the scalp, palms, and soles.

Eleven new molecular drug targets receive approval in 2025, expanding treatment options for rare diseases, cancer, and infectious diseases.

Insilico Medicine ("Insilico," HKEX: 3696), a clinical-stage biotechnology company powered by generative AI, today announced the initiation of the Phase III clinical trial for Rentosertib, its ...

As a head-to-head Phase III trial comparing sac-TMT plus pembrolizumab with the first-line standard of care (immunotherapy plus chemotherapy), OptiTROP-Lung06 demonstrated the superiority of replacing ...

Greenwich LifeSciences is a single-asset biotech focused on GLSI-100, an immunotherapy for HER2-positive breast cancer. Learn ...

SHANGHAI, July 7, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and ...

On June 30, Cogent Bioscience Inc. (NASDAQ:COGT) disclosed that it filed a New Drug Application for bezuclastinib, a drug for ...